| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | Ausblick | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 86.22 |
| Baillie Gifford & Co. | 11.47 |
| Baillie Gifford & Co. | 11.24 |
| The Vanguard Group, Inc. | 6.90 |
| Vanguard Group, Inc. (Subfiler) | 6.44 |
| Flagship Ventures Management, Inc. | 4.42 |
| State Street Corp. | 3.73 |
| BlackRock Fund Advisors | 3.12 |
| Robert S. Langer, DSc | 2.89 |
| Vanguard Total Stock Market Index Fund | 2.51 |
| Vanguard International Growth Fund | 2.49 |
| Scottish Mortgage Investment Trust Plc | 2.31 |
| Vanguard 500 Index Fund | 1.93 |
| BlackRock Institutional Trust Co. NA | 1.88 |
| Coatue Management LLC | 1.74 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 760 | 830 | 1’300 | 2’700 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.00 | 0.18 | 0.07 | 0.62 | 6.82 |
Bilanz (in Mio. EUR) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 783 | 1’563 | 1’129 | 6’298 | 16’071 |
| Summe Anlagevermögen | 641 | 1’574 | 1’311 | 2’799 | 15’061 |
| Summe Aktiva | 1’084 | 1’962 | 1’589 | 7’337 | 24’869 |
Bilanz (in Mio. EUR) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 16 | 44 | 136 | 238 | 916 |
| Summe Fremdkapital | 459 | 432 | 415 | 4’775 | 10’724 |
| Summe Eigenkapital | 625 | 1’530 | 1’175 | 2’561 | 14’145 |
| Summe Passiva | 1’084 | 1’962 | 1’589 | 7’337 | 24’869 |
Adresse
| 200 Technology Square, 02139 Cambridge | |
| Telefon | +1 (617) 714-6500 |
| URL | http://www.modernatx.com |
Management
|
Arpa Garay
Chief Commercial Officer |
|
Charbel Haber
Senior Vice President-Regulatory Affairs |
|
David W. Meline
Chief Financial Officer |
|
Elizabeth E. Tallett
Independent Director |
|
Elizabeth G. Nabel
Independent Director |
|
Francois Nader
Independent Non-Executive Director |
|
Jacqueline Miller
Senior VP-Infectious Disease Development |
|
John Lepore
Senior Vice President-Government Engagement |
|
Jonathan Hoggatt
Director-Hematology |
|
José M. Vega
Chief Safety Officer |
|
Juan Andres
Chief Technical Operations & Quality Officer |
|
Kate Cronin
Chief Brand Officer |
|
Lavina A. Talukdar
Senior Vice President & Head-Investor Relations |
|
Marcello Damiani
Chief Digital & Operational Excellence Officer |
|
Melanie Ivarsson
Chief Development Officer |
|
Noubar B. Afeyan
Chairman |
|
Patrick Norman Bergstedt
Senior Vice President-Commercial Vaccines |
|
Paul Burton
Chief Medical Officer |
|
Paul L. Sagan
Independent Non-Executive Director |
|
Paula Hammond
Scientific Advisory Board |
|
Robert S. Langer
Independent Non-Executive Director |
|
Sandra J. Horning
Independent Director |
|
Shannon Thyme Klinger
Secretary & Chief Legal Officer |
|
Stephen A. Berenson
Independent Non-Executive Director |
|
Stephen Hoge
President |
|
Stéphane Bancel
Chief Executive Officer & Director |
|
Tracey Franklin
Chief Human Resources Officer |